TY - JOUR
T1 - In vitro release of growth factors from platelet-rich fibrin (PRF)
T2 - a proposal to optimize the clinical applications of PRF
AU - Su, Chen Yao
AU - Kuo, Ya Po
AU - Tseng, Yu Hong
AU - Su, Ching Hua
AU - Burnouf, Thierry
N1 - Funding Information:
This study was supported by the National Science Council of Taiwan, ROC (NSC 97-2811-B-038-007).
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/7
Y1 - 2009/7
N2 - Objective: Determine the release of growth factors (GF) from platelet-rich fibrin (PRF) and supernatant serum to optimize clinical use. Study design: Platelet-derived growth factors-AB (PDGF-AB), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) were quantified in PRF releasate and in the supernatant serum (N = 8) over 300 minutes after clot formation. Protein profiles were determined by SDS-PAGE. Results: Mean quantity of PDGF-AB, TGF-ß1, VEGF, and EGF in PRF releasate increased significantly to about 52, 72, 1, and 3 ng, respectively, whereas mean IGF-1 content remained at 250 ng. GF was also found in serum supernatant. Protein profiles of the releasates and the supernatant serum were similar. Conclusion: The PRF membrane should be used immediately after formation to maximize release of GF to the surgical site. The remaining fluid can be recovered as an additional source of GF for grafting.
AB - Objective: Determine the release of growth factors (GF) from platelet-rich fibrin (PRF) and supernatant serum to optimize clinical use. Study design: Platelet-derived growth factors-AB (PDGF-AB), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) were quantified in PRF releasate and in the supernatant serum (N = 8) over 300 minutes after clot formation. Protein profiles were determined by SDS-PAGE. Results: Mean quantity of PDGF-AB, TGF-ß1, VEGF, and EGF in PRF releasate increased significantly to about 52, 72, 1, and 3 ng, respectively, whereas mean IGF-1 content remained at 250 ng. GF was also found in serum supernatant. Protein profiles of the releasates and the supernatant serum were similar. Conclusion: The PRF membrane should be used immediately after formation to maximize release of GF to the surgical site. The remaining fluid can be recovered as an additional source of GF for grafting.
UR - http://www.scopus.com/inward/record.url?scp=67649421620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649421620&partnerID=8YFLogxK
U2 - 10.1016/j.tripleo.2009.02.004
DO - 10.1016/j.tripleo.2009.02.004
M3 - Article
C2 - 19451002
AN - SCOPUS:67649421620
SN - 1079-2104
VL - 108
SP - 56
EP - 61
JO - Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology
JF - Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology
IS - 1
ER -